Home » Author Archives: Catherine Skari (page 4)

Author Archives: Catherine Skari

Bluebird puts €1.58m price on gene therapy Zynteglo

  Bluebird bio Inc. set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe earlier this month to to treat patients 12 years and older with transfusion-dependent β-thalassaemia (TDT), who have no matching donor for a stem ...

Read More »

FROM PUMP TO PILL by Chanapa Tantibanchachai

Winner Story #1 – International Thalassaemia Day 2018   »As I reflect on my past, present and future as a thalassemia patient, I can’t help but be in complete awe of the clinical advances that have been made just in the past two and a half decades that I’ve been ...

Read More »

مييا حمااكة واقعي مع الثالس by Hanady Alsanwi

Winner Story #2– International Thalassaemia Day 2018   متكرر ما بني الفرتة واألخرى ونظرات ً ال يفارق جسدي ونقل دما ً للمستشفى وآملا يف اعني و الدي ً خوفا و صعوبة احلياة اجلسدية واحلياة الواقعية يف ظل احلروب الدائمة يف بالدنا وصعوبة العيش وانقطاع االدوية بشكل مستمر , اصبح اآلمل ...

Read More »

TIF’s e-registry for patients with thalassaemia is ready for piloting

  TIF with support from Celgene Corporation, has developed a disease specific e-registry with health record for patients with thalassaemia. This e-registry is now completed, as a first version, and is ready to be piloted in selected centres in Cyprus, Greece and Bulgaria. After piloting and user comments, the e-registry ...

Read More »